EUVIMEDEUVIMED entdecken
Crossref

Dendritic Cell‐Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease

Wenzhe Yi, Fang Sun, Xindi Qian, Xiaoxuan Xu, Dan Yan, Zhiwen Zhao, Leiming Xu, Dangge Wang, Yaping Li iD

Advanced Materials · 2025

DOI: 10.1002/adma.202420113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Wenzhe Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203,…. Hauptthemen laut MEDLINE: Dendritic Cells, Inflammatory Bowel Diseases, Immunologic Factors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Laboratory Program, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation is a key driver of intestinal inflammatory diseases, such as inflammatory bowel disease (IBD). While biologics have demonstrated notable success in treating some patients, there remains a critical need for alternative therapeutic strategies to address primary and secondary non‐responders. In this study, a dendritic cell (DC)‐based biohybrid immunomodulator is developed to alleviate intestinal inflammation, demonstrating remarkable efficacy in combating IBD. This biohybrid immunomodulator is engineered by conjugating resolvin E1‐loaded liposomes with Fas ligand (FasL)‐transfected DCs. Elevated Fas expression is observed in intestinal tissue samples from IBD patients, and the immunomodulator effectively reduced inflammation by selectively eliminating Fas + CD8 + T cells and neutrophils. The therapeutic potential of this approach is validated in both mouse and rabbit models of IBD, where it exhibites significant anti‐inflammatory effects. Furthermore, the immunomodulator can be manufactured using human peripheral blood mononuclear cells and bone marrow‐derived DCs, demonstrating a robust capacity to induce T cell apoptosis. This study presents a feasible and customizable strategy for mitigating intestinal inflammation, offering a promising advancement in the treatment of IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsInflammatory Bowel DiseasesImmunologic FactorsAnimalsHumansMiceLiposomesRabbitsMice, Inbred C57BLFas Ligand ProteinApoptosisDisease Models, AnimalInflammationIntestinesCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

dendritic cellsfas/fas legend interactioninflammatory bowel diseaseliposomes

Substanzen

Immunologic FactorsLiposomesFas Ligand Protein

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
  • Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264000, China.

ORCID-Profile: Yaping Li

Förderung

  • National Natural Science Foundation of China
  • Shandong Laboratory Program
  • Science and Technology Commission of Shanghai Municipality
  • Key Technologies Research and Development Program

Zitieren

APA

Yi, W., Sun, F., Qian, X., Xu, X., Yan, D., Zhao, Z., Xu, L., Wang, D., & Li, Y. (2025). Dendritic Cell‐Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease. Advanced Materials. https://doi.org/10.1002/adma.202420113

Vancouver

Yi W, Sun F, Qian X, Xu X, Yan D, Zhao Z, et al. Dendritic Cell‐Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease. Advanced Materials. 2025. doi:10.1002/adma.202420113

BibTeX
@article{Yi2025,
  author = {Yi, Wenzhe and Sun, Fang and Qian, Xindi and Xu, Xiaoxuan and Yan, Dan and Zhao, Zhiwen and Xu, Leiming and Wang, Dangge and Li, Yaping},
  title = {Dendritic Cell‐Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease},
  journal = {Advanced Materials},
  year = {2025},
  doi = {10.1002/adma.202420113}
}
Kostenlos starten →